- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.10. | ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026 | 1 | GlobeNewswire (USA) | ||
| 10.08. | ProKidney GAAP EPS of -$0.15 misses by $0.01, revenue of $0.15M in-line | 1 | Seeking Alpha | ||
| 10.08. | PROKIDNEY CORP. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.08. | PROKIDNEY CORP. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 17.06. | Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel's Accelerated Approval Path | 1 | Insider Monkey | ||
| 02.06. | ProKidney beruft Kenneth Locke zum Chief Technical Officer | 2 | Investing.com Deutsch | ||
| PROKIDNEY Aktie jetzt für 0€ handeln | |||||
| 02.06. | ProKidney Appoints Kenneth Locke as Chief Technical Officer | 247 | GlobeNewswire (Europe) | WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease... ► Artikel lesen | |
| 18.05. | ProKidney GAAP EPS of -$0.14 beats by $0.01, revenue of $0.23M beats by $0.03M | 1 | Seeking Alpha | ||
| 15.05. | ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates | 1 | Zacks | ||
| 15.05. | PROKIDNEY CORP. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | ProKidney Reports First Quarter 2026 Financial Results and Business Highlights | 470 | GlobeNewswire (Europe) | On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027Peer-reviewed results from the Phase... ► Artikel lesen | |
| 15.05. | PROKIDNEY CORP. - 10-Q, Quarterly Report | 8 | SEC Filings | ||
| 25.03. | ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer | 355 | GlobeNewswire (Europe) | WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney... ► Artikel lesen | |
| 10.11.25 | ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates | 383 | GlobeNewswire (Europe) | Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of... ► Artikel lesen | |
| 06.11.25 | ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025 | 542 | GlobeNewswire (Europe) | In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progressionBilateral... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIVOSIM LABS | 0,179 | +1,13 % | VivoSim Labs, Inc.: VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling | ||
| INOVIO PHARMACEUTICALS | 0,728 | +1,89 % | Inovio wins case in dispute with VGXI, GeneOne Life Science | ||
| EQUILLIUM | 1,195 | 0,00 % | Equillium, Inc.: Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504 | On track to initiate dosing by early November 2026; topline Phase 1 proof-of-mechanism data anticipated approximately six months following study initiation Randomized, double-blind, placebo-controlled... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 1,510 | 0,00 % | Enveric completes drug absorption studies for EB-003 candidate | ||
| REGENCELL BIOSCIENCE | 10,800 | 0,00 % | Holzer & Holzer LLC: RGC INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of the June 23, 2026 Lead Plaintiff Deadline in the Regencell Bioscience Holdings Limited Securities Class Action | Atlanta, Georgia--(Newsfile Corp. - June 16, 2026) - A shareholder class action lawsuit has been filed against Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC).... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 12,610 | 0,00 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | ||
| VERRICA PHARMACEUTICALS | 3,130 | 0,00 % | Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH (VP-102) for the Treatment of Common Warts | - Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan - - Verrica maintains ownership of global... ► Artikel lesen | |
| RELMADA THERAPEUTICS | 2,740 | 0,00 % | Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer | Brings nearly three decades of leadership spanning NMIBC, corporate strategy and business development to help advance NDV-01 and support the Company's long-term growth and value creation. CORAL GABLES... ► Artikel lesen | |
| BOUNDLESS BIO | 2,430 | -0,41 % | Biotech Stocks At 52-Week Highs - Eloxx Pharmaceuticals, Prelude Therapeutics, argenX, Boundless Bio, Corcept Therapeutics | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 21, 2026, as new trials continued enrolment and companies released positive clinical research data.Eloxx... ► Artikel lesen | |
| BIOATLA | 1,800 | +3,75 % | BioAtla, Inc. - S-1, General form for registration of securities | ||
| TRANSCODE THERAPEUTICS | 1,700 | +2,41 % | TransCode Therapeutics, Inc.: TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up | Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumors
In the 14 efficacy-evaluable patients:
71.4% stable disease... ► Artikel lesen | |
| PEPGEN | 2,720 | 0,00 % | PepGen GAAP EPS of -$0.26 | ||
| VOR BIOPHARMA | 18,930 | -0,05 % | Vor Biopharma: Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis | More than 94% of participants achieved a =5-point MG-ADL improvement at Week 48 42% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing... ► Artikel lesen | |
| LEONABIO | 5,620 | -0,88 % | LeonaBio, Inc.: LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update | On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected... ► Artikel lesen | |
| QIAGEN | 42,820 | -0,02 % | Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur | DJ Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur
DOW JONES--Der Finanzinvestor EQT will einem Agenturbericht zufolge den Diagnostikspezialisten Qiagen übernehmen. Wie... ► Artikel lesen |
PROKIDNEY CORP gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,440 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROKIDNEY CORP finden Sie auf Wallstreet Online.